Inhibition of MMP-9, the primary MMP implicated in stroke-induced neuroinflammation and the biphasic disruption of the blood–brain barrier, has shown mixed results in experimental studies depending on the timing of administration [102]. The gene discussed is MMP9; the disease is stroke disorder.